Chickasaw Capital Management LLC held its position in shares of Core Laboratories N.V. (NYSE:CLB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,000 shares of the oil and gas company’s stock at the end of the second quarter. Chickasaw Capital Management LLC’s holdings in Core Laboratories N.V. were worth $304,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in CLB. Parallel Advisors LLC boosted its position in shares of Core Laboratories N.V. by 33.4% in the first quarter. Parallel Advisors LLC now owns 891 shares of the oil and gas company’s stock valued at $101,000 after buying an additional 223 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Core Laboratories N.V. during the first quarter valued at $106,000. Advisory Services Network LLC bought a new position in shares of Core Laboratories N.V. during the first quarter valued at $118,000. FNY Managed Accounts LLC bought a new position in shares of Core Laboratories N.V. during the first quarter valued at $123,000. Finally, First Bank & Trust boosted its position in shares of Core Laboratories N.V. by 2.7% in the first quarter. First Bank & Trust now owns 1,411 shares of the oil and gas company’s stock valued at $163,000 after buying an additional 37 shares in the last quarter.
Shares of Core Laboratories N.V. (NYSE CLB) opened at 88.73 on Friday. The company’s 50-day moving average price is $100.45 and its 200-day moving average price is $107.96. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 54.44 and a beta of 1.60. Core Laboratories N.V. has a 12 month low of $88.55 and a 12 month high of $125.83.
Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The company had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. During the same quarter last year, the business posted $0.35 earnings per share. The firm’s revenue was up 10.7% compared to the same quarter last year. Analysts anticipate that Core Laboratories N.V. will post $2.09 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 14th. Investors of record on Monday, July 17th were given a $0.55 dividend. The ex-dividend date of this dividend was Thursday, July 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.48%. Core Laboratories N.V.’s dividend payout ratio (DPR) is presently 134.15%.
TRADEMARK VIOLATION NOTICE: This piece was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/08/18/chickasaw-capital-management-llc-has-304000-position-in-core-laboratories-n-v-clb-updated-updated.html.
Several brokerages have weighed in on CLB. Royal Bank Of Canada set a $145.00 price objective on Core Laboratories N.V. and gave the company a “buy” rating in a report on Saturday, June 17th. BidaskClub cut Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Morgan Stanley dropped their price objective on Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, August 7th. Scotiabank set a $136.00 price objective on Core Laboratories N.V. and gave the company a “hold” rating in a report on Saturday, April 22nd. Finally, ValuEngine raised Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $117.17.
Core Laboratories N.V. Company Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
